Security
Indivior Pharmaceuticals, Inc. Common Stock · INDV
INDVNASDAQCommon stockCurrentCIK 1625297Updated Oct 3, 2026
Name history
INDIVIOR PLC · through Jan 8, 2026
INDV price & chart
Loading TradingView…
NASDAQ:INDV on TradingView ↗About the company
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together - with science, people living with OUD, public health champions, and communities - we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.
In the news
Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th News provided by Indivior PLC Oct 16, 2025, 16:04 ET Share this article Share to X Share this article Share to X RICHMOND, Va. , Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV ) today announced that it ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,201,000,000Source | 1,319,000,000Source | 1,954,000,000Source | 1,769,000,000Source |
| Property, Plant and Equipment, NetUSD | 144,000,000Source | 100,000,000Source | 84,000,000Source | — |
| GoodwillUSD | 2,000,000Source | 2,000,000Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 195,000,000Source | 319,000,000Source | — | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 253,000,000Source | 254,000,000Source | — | — |
| Inventory, NetUSD | 153,000,000Source | 178,000,000Source | — | — |
| Assets, CurrentUSD | 652,000,000Source | 839,000,000Source | — | — |
| Prepaid Expense and Other Assets, CurrentUSD | — | 53,000,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 26,000,000Source | 39,000,000Source | — | — |
| Other Assets, NoncurrentUSD | 27,000,000Source | 29,000,000Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,300,000,000Source | 1,668,000,000Source | 1,954,000,000Source | 1,718,000,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 62,000,000Source | 62,000,000Source | — | — |
| Additional Paid in CapitalUSD | 112,000,000Source | 90,000,000Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -243,000,000Source | -454,000,000Source | — | — |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -30,000,000Source | -36,000,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | -98,000,000Source | -348,000,000Source | — | — |
| Liabilities and EquityUSD | 1,201,000,000Source | 1,319,000,000Source | — | — |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 914,000,000Source | 939,000,000Source | — | — |
| Operating Lease, Liability, CurrentUSD | 10,000,000Source | 10,000,000Source | — | — |
| Accounts Payable, CurrentUSD | 48,000,000Source | 63,000,000Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | 22,000,000Source | 32,000,000Source | — | — |
| Other Liabilities, NoncurrentUSD | 21,000,000Source | 18,000,000Source | — | — |
| Additional Financial Items | ||||
| AllowanceAccountForCreditLossesOfFinancialAssetsUSD | — | — | 2,000,000Source | 2,000,000Source |
| CurrentFinancialAssetsAtFairValueThroughProfitOrLossUSD | — | — | 10,000,000Source | 10,000,000Source |
| CurrentTaxAssetsCurrentUSD | — | — | 0Source | 5,000,000Source |
| CurrentTaxLiabilitiesCurrentUSD | — | — | 18,000,000Source | 9,000,000Source |
| DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactionsUSD | — | — | 14,000,000Source | -11,000,000Source |
| DeferredTaxAssetsUSD | — | — | 268,000,000Source | 219,000,000Source |
| DeferredTaxLiabilityAssetUSD | — | — | -268,000,000Source | -219,000,000Source |
| IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAssetUSD | — | — | 11,000,000Source | — |
| IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAssetUSD | — | — | 1,000,000Source | -1,000,000Source |
| IssuedCapitalUSD | — | — | 68,000,000Source | 68,000,000Source |
| Long-term Debt, Current MaturitiesUSD | 29,000,000Source | 18,000,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 290,000,000Source | 315,000,000Source | — | — |
| Short-term InvestmentsUSD | 0Source | 1,000,000Source | — | — |
| TradeAndOtherCurrentPayablesUSD | — | — | 743,000,000Source | 617,000,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | — | — | 2,000,000Source | -53,000,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 10,000,000Source | 29,000,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 26,000,000Source | 24,000,000Source | — | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -3,000,000Source | 1,000,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | -18,000,000Source | 45,000,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | -46,000,000Source | 6,000,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -27,000,000Source | 36,000,000Source | — | — |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 0Source | 0Source | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -66,000,000Source | 69,000,000Source | — | — |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | 0Source | 0Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 66,000,000Source | 29,000,000Source | — | — |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 5,000,000Source | 22,000,000Source | — | — |
| Payments for Repurchase of Common StockUSD | 11,000,000Source | 173,000,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -30,000,000Source | -102,000,000Source | — | — |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | -2,000,000Source | — | — |
| Repayments of Long-term DebtUSD | 17,000,000Source | 240,000,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 195,000,000Source | 319,000,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 34,000,000Source | 32,000,000Source | — | — |
| Income Taxes Paid, NetUSD | 38,000,000Source | 46,000,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 0Source | — | — |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | — | — | -33,000,000Source | -21,000,000Source |
| AdjustmentsForDeferredTaxOfPriorPeriodsUSD | — | — | 7,000,000Source | -12,000,000Source |
| AdjustmentsForSharebasedPaymentsUSD | — | — | 22,000,000Source | 16,000,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | — | — | -11,000,000Source | -3,000,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 26,000,000Source | 24,000,000Source | — | — |
| Capitalized Computer Software, AmortizationUSD | 0Source | 3,000,000Source | — | — |
| DepreciationUSD | 10,000,000Source | 12,000,000Source | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | 0Source | -9,000,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -1,000,000Source | 2,000,000Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | -3,000,000Source | -195,000,000Source | — | — |
| GeneralAndAdministrativeExpenseUSD | — | — | 575,000,000Source | 545,000,000Source |
| GoodwillUSD | 2,000,000Source | 2,000,000Source | — | — |
| Goodwill and Intangible Asset ImpairmentUSD | — | 0Source | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | 5,000,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 29,000,000Source | 11,000,000Source | — | — |
| InterestExpenseNonoperatingUSD | 45,000,000Source | 41,000,000Source | — | — |
| InterestPaidClassifiedAsOperatingActivitiesUSD | — | — | 32,000,000Source | 24,000,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | — | — | 42,000,000Source | 15,000,000Source |
| Inventory Write-downUSD | 26,000,000Source | 36,000,000Source | — | — |
| Investment Income, InterestUSD | 22,000,000Source | 23,000,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 210,000,000Source | 2,000,000Source | — | — |
| Operating ExpensesUSD | — | 925,000,000Source | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | — | 8,000,000Source | 9,000,000Source |
| PaymentsToAcquireOrRedeemEntitysSharesUSD | — | — | 33,000,000Source | 90,000,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | 0Source | 0Source |
| Proceeds from Issuance of Common StockUSD | 2,000,000Source | 3,000,000Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | 0Source | 332,000,000Source | — | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | 45,000,000Source | 1,000,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | 12,000,000Source | 3,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,239,000,000Source | 1,188,000,000Source | 1,093,000,000Source | 901,000,000Source |
| Cost of RevenueUSD | 246,000,000Source | 231,000,000Source | — | — |
| Selling, General and Administrative ExpenseUSD | 634,000,000Source | 618,000,000Source | 811,000,000Source | 763,000,000Source |
| Operating Income (Loss)USD | 262,000,000Source | 32,000,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 239,000,000Source | 14,000,000Source | — | — |
| Income Tax Expense (Benefit)USD | 29,000,000Source | 11,000,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 210,000,000Source | 2,000,000Source | — | — |
| Earnings Per Share, BasicUSD per share | 1.68Source | 0.02Source | — | — |
| Earnings Per Share, DilutedUSD per share | 1.64Source | 0.02Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 125,000,000Source | 132,000,000Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 128,000,000Source | 133,000,000Source | — | — |
| Interest Expense (non-operating)USD | 45,000,000Source | 41,000,000Source | — | — |
| Additional Financial Items | ||||
| AverageEffectiveTaxRatenumber | — | — | -1Source | 0.44Source |
| Capitalized Computer Software, AmortizationUSD | 0Source | 3,000,000Source | — | — |
| Current Income Tax Expense (Benefit)USD | 75,000,000Source | 5,000,000Source | — | — |
| CurrentTaxExpenseIncomeUSD | — | — | 61,000,000Source | 51,000,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD | — | — | -56,000,000Source | -106,000,000Source |
| DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossUSD | — | — | 15,000,000Source | 13,000,000Source |
| DepreciationRightofuseAssetsUSD | — | — | 9,000,000Source | 8,000,000Source |
| EmployeeBenefitsExpenseUSD | — | — | 309,000,000Source | 240,000,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | — | — | 22,000,000Source | 16,000,000Source |
| ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilitiesUSD | — | — | 22,000,000Source | 21,000,000Source |
| FinanceCostsUSD | — | — | 38,000,000Source | 29,000,000Source |
| FinanceIncomeUSD | — | — | 43,000,000Source | 19,000,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -1,000,000Source | 2,000,000Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | -3,000,000Source | -195,000,000Source | — | — |
| GeneralAndAdministrativeExpenseUSD | — | — | 575,000,000Source | 545,000,000Source |
| Gross ProfitUSD | 994,000,000Source | 957,000,000Source | 907,000,000Source | 742,000,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillUSD | — | — | 0Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 255,000,000Source | 28,000,000Source | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | — | — | -1,000,000Source | -42,000,000Source |
| Interest Expense, DebtUSD | 38,000,000Source | 32,000,000Source | — | — |
| InterestExpenseOnLeaseLiabilitiesUSD | — | — | 3,000,000Source | 2,000,000Source |
| Investment Income, InterestUSD | 22,000,000Source | 23,000,000Source | — | — |
| Operating ExpensesUSD | — | 925,000,000Source | — | — |
| OtherFinanceCostUSD | — | — | 1,000,000Source | 0Source |
| OtherIncomeUSD | — | — | 6,000,000Source | 8,000,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | — | — | 14,000,000Source | 12,000,000Source |
| ProfitLossBeforeTaxUSD | — | — | 1,000,000Source | -95,000,000Source |
| ProfitLossFromOperatingActivitiesUSD | — | — | -4,000,000Source | -85,000,000Source |
| ResearchAndDevelopmentExpenseUSD | — | — | 106,000,000Source | 72,000,000Source |
| RevenueFromInterestUSD | — | — | 43,000,000Source | 18,000,000Source |
Offerings
Registration 333-298637
Filing attachments
tm2623753d8_ex99-1.htm · 425 · 2026-09-17
EX-99.1 2 tm2623753d8_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend Payment of Special Dividend Contingent upon Closing of the Pending Merger Transaction Richmond, Va., September 17, 2026 - Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the amount of (i) $8.13 per share of Indivior common stock payable to holders of recor…
Read attachment ↗tm2623753d7_ex99-1.htm · 8-K · 2026-09-17
EX-99.1 2 tm2623753d7_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend Payment of Special Dividend Contingent upon Closing of the Pending Merger Transaction Richmond, Va., September 17, 2026 - Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the amount of (i) $8.13 per share of Indivior common stock payable to holders of recor…
Read attachment ↗d166865dex991.htm · 8-K · 2026-08-03
EX-99.1 2 d166865dex991.htm EX-99.1 EX-99.1 Merger of Equals to Create a Diversified CNS Biopharmaceutical Leader with Significant Scale AUGUST 3, 2026 Exhibit 99.1 Forward Looking Statements This presentation, and any related oral statements made by representatives of Supernus or Indivior in connection with it, contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. From time to time, oral or wri…
Read attachment ↗d118566dex991.htm · 8-K · 2026-08-03
EX-99.1 2 d118566dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance • Q2’26 Total Net Revenue of $343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE ® Net Revenue of $253 Million in Q2’26, Up 21% YoY • Record Quarterly GAAP Net Income of $122 Million and Record Non-GAAP Net Income of $142 Million in Q2’26 • Record Quarterly Adjusted EBITDA of $186 Million in Q2’26, Up 111% YoY • Repurchased App…
Read attachment ↗d118566dex992.htm · 8-K · 2026-08-03
EX-99.2 3 d118566dex992.htm EX-99.2 EX-99.2 Q2 2026 Financial Results August 3, 2026 Indivior, Powering Recovery, Renewing Hope. Exhibit 99.2 IMPORTANT CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Q2 2026 Results | August 3, 2026 This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: potential deployment of capital to create long-term value for shareholders, inclu…
Read attachment ↗d28447dex991.htm · 8-K · 2026-08-03
EX-99.1 3 d28447dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”) is made and entered into as of August 1, 2026, by and between Supernus Pharmaceuticals, Inc., a Delaware corporation (“Supernus”) and the undersigned stockholder (the “Stockholder”) of Indivior Pharmaceuticals, Inc., a Delaware corporation (“Indivior”). WITNESSETH: WHEREAS, contemporaneously with the execution of this Agreement, Supernus, Indivior and Artemis Merger Sub Inc.…
Read attachment ↗